Background:\u00a0<\/strong>Synucleinopathies include a spectrum of disorders varying in features and severity, including idiopathic\/isolated REM sleep behaviour disorder (iRBD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB). Distinct brain atrophy patterns may already be seen in iRBD; however, how brain atrophy begins and progresses remains unclear.<\/p>\n Methods:\u00a0<\/strong>A multicentric cohort of 1276 participants (451 polysomnography-confirmed iRBD, 142 PD with probable RBD, 87 DLB, and 596 controls) underwent T1-weighted MRI and longitudinal clinical assessments. Brain atrophy was quantified using vertex-based cortical surface reconstruction and volumetric segmentation. The unsupervised machine learning algorithm, Subtype and Stage Inference (SuStaIn), was used to reconstruct spatiotemporal patterns of brain atrophy progression.<\/p>\n Findings:\u00a0<\/strong>SuStaIn identified two distinct subtypes of brain atrophy progression: 1) a \u00ab\u00a0cortical-first\u00a0\u00bb subtype, with atrophy beginning in the frontal lobes and involving the subcortical structures at later stages; and 2) a \u00ab\u00a0subcortical-first\u00a0\u00bb subtype, with atrophy beginning in the limbic areas and involving cortical structures at later stages. Both cortical- and subcortical-first subtypes were associated with a higher rate of increase in MDS-UPDRS-III scores over time, but cognitive decline was subtype-specific, being associated with advancing stages in patients classified as cortical-first but not subcortical-first. Classified patients were more likely to phenoconvert over time compared to stage 0\/non-classified patients. Among the 88 patients with iRBD who phenoconverted during follow-up, those classified within the cortical-first subtype had a significantly increased likelihood of developing DLB compared to PD, unlike those classified within the subcortical-first subtype.<\/p>\n Interpretation:\u00a0<\/strong>There are two distinct atrophy progression subtypes in iRBD, with the cortical-first subtype linked to an increased likelihood of developing DLB, while both subtypes were associated with worsening parkinsonian motor features. This underscores the potential utility of subtype identification and staging for monitoring disease progression and patient selection for trials.<\/p>\n","protected":false},"author":14,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-16537","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"\n